The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease

• Published in: International immunopharmacology Vol. 116; pp. 109756 - None
• Main Authors: Hameiri-Bowen, Dan, Yindom, Louis-Marie, Sovershaeva, Evgeniya, Bandason, Tsitsi, Mayini, Justin, M Rehman, Andrea, Simms, Victoria, Gift Ngwira, Lucky, Flagestad, Trond, Jarl Gutteberg, Tore, McHugh, Grace, Abbas Ferrand, Rashida, Rowland-Jones, Sarah L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2023; Elsevier; Elsevier Science
• Subjects: Adolescent; Anti-Bacterial Agents - therapeutic use; Azithromycin; Azithromycin - therapeutic use; Biomarkers; Child; CRP; Cytokines; Double-Blind Method; HIV; HIV Infections - complications; HIV Infections - drug therapy; Humans; Immunomodulation; Lung Disease; Lung Diseases - drug therapy; CRP; HIV; Cytokines; Immunomodulation; Lung Disease; Azithromycin

[Display omitted] •Azithromycin treatment reduced plasma levels of CRP, E-Selectin and MMP-10 in children with HIV-associated chronic lung disease.•Limited immunomodulatory properties observed in large panel of soluble markers.•No treatment effects were sustained after cessation of treatment. HIV-as...